Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases

NCT02595905 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT02595905
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02595905 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
September 15, 2016
Completion date
March 21, 2025
Enrollment
344 (actual)
Sites
810

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic brca hereditary breast carcinoma, metastatic breast carcinoma, metastatic malignant neoplasm in the brain, metastatic triple-negative breast carcinoma, recurrent breast carcinoma, stage iv breast cancer ajcc v6 and v7